Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 167

Sort by

Sort Order Select

Journal Articles

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

Blood (2024) 144 (16): 1722–1731.

https://doi.org/10.1182/blood.2024023840

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular taxonomy of myelodysplastic syndromes and its clinical implications

Elsa Bernard, Robert P. Hasserjian, Peter L. Greenberg, Juan E. Arango Ossa, Maria Creignou, Heinz Tuechler, Jesus Gutierrez-Abril, Dylan Domenico, Juan S. Medina-Martinez, Max Levine, Konstantinos Liosis, Noushin Farnoud, Maria Sirenko, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Yasuhito Nannya, Olivier Kosmider, Matilde Y. Follo, Felicitas Thol, Lurdes Zamora, Ronald F. Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio P. S. Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Michaela Fontenay, Joop H. Jansen, José Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Seishi Ogawa, Mario Cazzola, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2024) 144 (15): 1617–1632.

https://doi.org/10.1182/blood.2023023727

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular and clinical presentation of UBA1 -mutated myelodysplastic syndromes

Maria Sirenko, Elsa Bernard, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E. Arango Ossa, Olivier Kosmider, Robert Hasserjian, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Carmelo Gurnari, Matilde Yung Follo, Felicitas Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Birgitta Sander, Elisa Orna, Katharina Zoldan, Lea Naomi Eder, Wolfgang R. Sperr, Renate Thalhammer, Christina Ganster, Lionel Adès, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio P. S. Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B. Beck, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2024) 144 (11): 1221–1229.

https://doi.org/10.1182/blood.2023023723

Published: 2024

Includes: Supplemental data

Journal Articles

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee

Francesco Onida, Nico Gagelmann, Yves Chalandon, Guido Kobbe, Marie Robin, Argiris Symeonidis, Theo de Witte, Raphael Itzykson, Madlen Jentzsch, Uwe Platzbecker, Valeria Santini, Guillermo Sanz, Christof Scheid, Eric Solary, Peter Valent, Raffaela Greco, Isabel Sanchez-Ortega, Ibrahim Yakoub-Agha, Lisa Pleyer

Blood (2024) 143 (22): 2227–2244.

https://doi.org/10.1182/blood.2023023476

Published: 2024

Includes: Supplemental data

Journal Articles

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Esther Natalie Oliva, Uwe Platzbecker, Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Pierre Fenaux, Jake Shortt, Rami S. Komrokji, Christopher Pelligra, Shien Guo, Jennifer Lord-Bessen, Hong Xiao, Aylin Yucel, Dimana Miteva, Shelonitda Rose, Sandra Kreitz, Mikkael A. Sekeres, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2023-174660

Published: 2023

Journal Articles

Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms

Blood (2023) 142 (Supplement 1): 4595.

https://doi.org/10.1182/blood-2023-189053

Published: 2023

Journal Articles

Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1863.

https://doi.org/10.1182/blood-2023-186222

Published: 2023

Journal Articles

The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes

Amer M. Zeidan, Rami S. Komrokji, Rena Buckstein, Valeria Santini, Shelonitda Rose, Priya Malini, Glen Lew, Dimple Aggarwal, Karen L. Keeperman, Huijing Jiang, Ana Carolina Giuseppi, Jennie Zhang, Thomas Cluzeau, Jake Shortt, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 6503.

https://doi.org/10.1182/blood-2023-178635

Published: 2023

Journal Articles

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Amer M. Zeidan, Michael R. Savona, Yazan F. Madanat, Pierre Fenaux, Rami S. Komrokji, Anna Jonášová, Thomas Illmer, Libo Sun, Tymara Berry, Faye M. Feller, Shyamala Navada, Valeria Santini, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 6478.

https://doi.org/10.1182/blood-2023-180962

Published: 2023

Journal Articles

Improved Overall Survival Among Luspatercept Responders and Predictors of Response

Blood (2023) 142 (Supplement 1): 1871.

https://doi.org/10.1182/blood-2023-186279

Published: 2023

Journal Articles

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Blood (2023) 142 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2023-181673

Published: 2023

Journal Articles

Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial

Mikkael A. Sekeres, Maria Diez-Campelo, Amer M. Zeidan, Uwe Platzbecker, Antoine Regnault, Kristin Creel, Nishan Sengupta, Ying Wan, Libo Sun, Qi Xia, Tymara Berry, Souria Dougherty, Sheetal Shah, Shyamala Navada, Valeria Santini, David Valcárcel

Blood (2023) 142 (Supplement 1): 6479.

https://doi.org/10.1182/blood-2023-181103

Published: 2023

Journal Articles

Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine

Valeria Santini, Cristina Amato, Sven De Pourcq, Roberta della Seta, Barbara Caciagli, Marco Gabriele Raddi, Angela Consagra, Luca Rigodanza, Giorgio Mattiuz, Marzia Defina, Sara Galimberti, Giacomo Maestrini, Alessandro Sanna

Blood (2023) 142 (Supplement 1): 6501.

https://doi.org/10.1182/blood-2023-190016

Published: 2023

Journal Articles

Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)

Uwe Platzbecker, Rami S. Komrokji, Amer M. Zeidan, Pierre Fenaux, Mikkael A. Sekeres, Michael R. Savona, Yazan F. Madanat, Anna Jonášová, Thomas Illmer, Laurie Sherman, Tymara Berry, Jennifer Riggs, Qi Xia, Shyamala Navada, Ying Wan, Fei Huang, Faye M. Feller, Valeria Santini

Blood (2023) 142 (Supplement 1): 4605.

https://doi.org/10.1182/blood-2023-181154

Published: 2023

Journal Articles

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Maria Borin, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Jan Philipp Bewersdorf, Olivier Nibourel, Marina Díaz-Beyá, Andres Jerez, Francisca Maria Hernandez, Kyra Velázquez Kennedy, Blanca Xicoy, Marta Ubezio, Alessia Campagna, Antonio Russo, Gabriele Todisco, Daniele Mannina, Stefania Bramanti, Matteo Zampini, Elena Riva, Marilena Bicchieri, Gianluca Asti, Filippo Viviani, Alessandro Buizza, Benedetta Tinterri, Andrea Bacigalupo, Alessandro Rambaldi, Francesco Passamonti, Fabio Ciceri, Victor Savevski, Armando Santoro, Najla H Al Ali, David A Sallman, Francesc Sole, Guillermo Garcia-Manero, Ulrich Germing, Shahram Kordasti, Valeria Santini, Guillermo Sanz, Wolfgang Kern, Anne Sophie Kubasch, Uwe Platzbecker, Maria Diez-Campelo, Jaroslaw P. Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M. Zeidan, Gastone Castellani, Rami S. Komrokji, Francesca Ieva, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 197.

https://doi.org/10.1182/blood-2023-182194

Published: 2023

Journal Articles

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Rami S. Komrokji, Valeria Santini, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, Tymara Berry, Laurie Sherman, Shyamala Navada, Faye M. Feller, Libo Sun, Qi Xia, Ying Wan, Fei Huang, Amer M. Zeidan, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 194.

https://doi.org/10.1182/blood-2023-181237

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Blood (2023) 142 (Supplement 1): 193.

https://doi.org/10.1182/blood-2023-178596

Published: 2023

Journal Articles

Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients

Luca Lanino, Anthony M. Hunter, Claudia Sala, Daniele Dall'Olio, Lorenzo Dall'Olio, Lisa Pleyer, Blanca Xicoy, Manja Meggendorfer, Elisabetta Sauta, Erica Travaglino, Marie Robin, Laura Palomo, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Giulia Rivoli, Massimo Bernardi, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Filippo Viviani, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Armando Santoro, Wolfgang Kern, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Angela Consagra, Najla H Al Ali, David A Sallman, Pierre Fenaux, Raphael Itzykson, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2023-184536

Published: 2023

Journal Articles

Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

Valeria Santini, Amer M. Zeidan, Pierre Fenaux, Yazan F. Madanat, Tymara Berry, Faye M. Feller, Libo Sun, Qi Xia, Ying Wan, Fei Huang, Michael R. Savona, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 4603.

https://doi.org/10.1182/blood-2023-179378

Published: 2023

Journal Articles

Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing

Blood (2023) 142 (Supplement 1): 122.

https://doi.org/10.1182/blood-2023-188292

Published: 2023

NARROW

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

Molecular taxonomy of myelodysplastic syndromes and its clinical implications

Molecular and clinical presentation of UBA1 -mutated myelodysplastic syndromes

Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee

Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study

Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms

Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes

The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Improved Overall Survival Among Luspatercept Responders and Predictors of Response

Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study

Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial

Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine

Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients

Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

Clinical Text Reports to Stratify Patients Affected with Myeloid Neoplasms Using Natural Language Processing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only